Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice

Vaccine

Volumn 30, Issue 2, 2012, Pages 254-264

  Dong, Libo ^a   Liu, Feng ^a   Fairman, Jeffery ^b   Hong, David K ^c   Lewis, David B ^c   Monath, Thomas ^d   Warner, John F ^d   Belser, Jessica A ^a   Patel, Jenish ^a   Hancock, Kathy ^a   Katz, Jacqueline M ^a   Lu, Xiuhua ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Colby Pharmaceutical Company ^*  (United States)

^c STANFORD UNIVERSITY   (United States)

^d Juvaris BioTherapeutics Inc   (United States)

Author keywords

Adjuvant; Antibody responses; CD4 + T cell immunity; CLDC; Cross clade protection; Dose sparing; Influenza A H5N1 virus

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VACCINE; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PROTECTION; DNA DRUG COMPLEX; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H5N1); MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CATIONS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA; DRUG CARRIERS; FEMALE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LIPOSOMES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, SUBUNIT;

EID: 84355162805     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.103     Document Type: Article

References (69)

1. Lewis D.B. Avian flu to human influenza. Annu Rev Med 2006, 57:139-154.
2. Viboud C., Miller M., Olson D., Osterholm M., Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 Pandemic in the US and comparison with past influenza seasons. PLoS Curr 2010, RRN1153.
3. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010, 59(33):1057-1062.
4. Taubenberger J.K., Morens D.M. Influenza: the once and future pandemic. Public Health Rep 2010, 125(SUPPL. 3):16-26.
5. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
6. Kawaoka Y., Krauss S., Webster R.G. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989, 63(11):4603-4608.
7. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59(RR-8):1-62.
8. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
9. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358(3):261-273.
10. Uyeki T.M. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009, 49(2):279-290.
11. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO; 2011. Available from: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_06_22/en/index.
12. Katz J.M., Veguilla V., Belser J.A., Maines T.R., Van Hoeven N., Pappas C., et al. The public health impact of avian influenza viruses. Poult Sci 2009, 88(4):872-879.
13. Cinatl J., Michaelis M., Doerr H.W. The threat of avian influenza A (H5N1). Part I: epidemiologic concerns and virulence determinants. Med Microbiol Immunol 2007, 196(4):181-190.
14. Neumann G., Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 2006, 12(6):881-886.
15. Sambhara S., Poland G.A. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Annu Rev Med 2010, 61:187-198.
16. Prieto-Lara E., Llanos-Mendez A. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. Vaccine 2010, 28(26):4328-4334.
17. Girard M.P., Katz J., Pervikov Y., Palkonyay L., Kieny M.P. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 2010, 28(42):6811-6820.
18. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523):1657-1664.
19. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(9272):1937-1943.
20. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-1351.
21. WHO. Tables on the Clinical trials of pandemic influenza prototype vaccines; 2010. Available from: http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/index.html.
22. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9(8):1057-1071.
23. Chu D.W., Hwang S.J., Lim F.S., Oh H.M., Thongcharoen P., Yang P.C., et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27(52):7428-7435.
24. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008, 198(5):642-649.
25. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3(2):e1665.
26. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197(5):667-675.
27. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26(19):2350-2359.
28. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006, 13(9):981-990.
29. Moran T.M., Park H., Fernandez-Sesma A., Schulman J.L. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999, 180(3):579-585.
30. Graham M.B., Braciale V.L., Braciale T.J. Influenza virus-specific CD4+ T helper type 2T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 1994, 180(4):1273-1282.
31. Hong D.K., Chang S., Botham C.M., Giffon T.D., Fairman J., Lewis D.B. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol 2010, 84(24):12691-12702.
32. Valensi J.P., Carlson J.R., Van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994, 153(9):4029-4039.
33. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(12):7335-7345.
34. Bernstein D.I., Cardin R.D., Bravo F.J., Strasser J.E., Farley N., Chalk C., et al. Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol 2009, 16(5):699-705.
35. Chang S., Warner J., Liang L., Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals 2009, 37(3):141-147.
36. Lay M., Callejo B., Chang S., Hong D.K., Lewis D.B., Carroll T.D., et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, 27(29):3811-3820.
37. Bernstein D.I., Farley N., Bravo F.J., Earwood J., McNeal M., Fairman J., et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2010, 28(21):3748-3753.
38. Gowen B.B., Fairman J., Smee D.F., Wong M.H., Jung K.H., Pace A.M., et al. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 2006, 69(3):165-172.
39. Lu X., Tumpey T.M., Morken T., Zaki S.R., Cox N.J., Katz J.M. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999, 73(7):5903-5911.
40. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004, 103(1-2):91-95.
41. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
42. Katz J.M., Lu X., Young S.A., Galphin J.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis 1997, 175(2):352-363.
43. Larson E.W., Dominik J.W., Rowberg A.H., Higbee G.A. Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infect Immun 1976, 13(2):438-447.
44. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
45. Brown D.M., Roman E., Swain S.L. CD4 T cell responses to influenza infection. Semin Immunol 2004, 16(3):171-177.
46. Yasuda K., Ogawa Y., Yamane I., Nishikawa M., Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol 2005, 77(1):71-79.
47. Yoshinaga T., Yasuda K., Ogawa Y., Nishikawa M., Takakura Y. DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells. Immunology 2007, 120(3):295-302.
48. Yasuda S., Yoshida H., Nishikawa M., Takakura Y. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages. Mol Pharm 2010, 7(2):533-542.
49. Nordly P., Madsen H.B., Nielsen H.M., Foged C. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin Drug Deliv 2009, 6(7):657-672.
50. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999, 163(3):1552-1561.
51. Jegerlehner A., Maurer P., Bessa J., Hinton H.J., Kopf M., Bachmann M.F. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007, 178(4):2415-2420.
52. Gowen B.B., Fairman J., Dow S., Troyer R., Wong M.H., Jung K.H., et al. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res 2009, 81(1):37-46.
53. Fairman J., Moore J., Lemieux M., Van Rompay K., Geng Y., Warner J., et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 2009, 5(3):141-150.
54. Cote P.J., Butler S.D., George A.L., Fairman J., Gerin J.L., Tennant B.C., et al. Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. J Med Virol 2009, 81(10):1760-1772.
55. Droebner K., Haasbach E., Fuchs C., Weinzierl A.O., Stevanovic S., Buttner M., et al. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 2008, 26(52):6965-6974.
56. Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87(4):300-308.
57. McKee A.S., MacLeod M.K., Kappler J.W., Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge?. BMC Biol 2010, 8:37.
58. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005, 23(SUPPL. 1):S10-S25.
59. Zhong W., Liu F., Dong L., Lu X., Hancock K., Reinherz E.L., et al. Significant impact of sequence variations in the nucleoprotein on CD8T cell-mediated cross-protection against influenza A virus infections. PLoS One 2010, 5(5):e10583.
60. Feng J.Q., Mozdzanowska K., Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 2002, 76(3):1369-1378.
61. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310(5753):1510-1512.
62. Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997, October, 159:95-103.
63. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8(1):34-47.
64. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172(9):5598-5605.
65. Mozdzanowska K., Furchner M., Washko G., Mozdzanowski J., Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997, 71(6):4347-4355.
66. Lundgren M., Persson U., Larsson P., Magnusson C., Smith C.I., Hammarstrom L., et al. Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. Eur J Immunol 1989, 19(7):1311-1315.
67. Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 1983, 131(6):2895-2902.
68. Cox R.J., Madhun A.S., Hauge S., Sjursen H., Major D., Kuhne M., et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27(13):1889-1897.
69. Nicholson K.G., Thompson C.I., Klap J.M., Wood J.M., Batham S., Newman R.W., et al. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 2009, 28(1):171-178.